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Background:  Lansoprazole, amoxicillin, and clarithromycin are commonly used drugs for eradication of 
Helicobacter pylori (H. pylori). A few studies reported that the eradication rate was influenced by the functional 
polymorphism of CYP2C19, whose product metabolizes proton pomp inhibitors including lansoprazole.   
Methods: This study examined the eradication rate among 67 participants in the polymorphism study who 
visited Daiko Medical Center, Nagoya University from July 2004 to October 2005. The participants aged 20 to 69 
years were classified into three group according to CYP2C19 genotype; rapid metabolizers (RM) with *1*1 
genotype, intermediate metabolizers (IM) with *1*2 or *1*3 genotype, and poor metabolizers (PM) with *2*2, *2*3, 
or *3*3 genotype. For the genotype classification, G681A (681G for *1 and 681A for *2) and G636A (636G for *1 
and  636A for *3) were genotyped by PCR with confronting two-pair primers (PCR-CTPP). They were also 
genotyped for IL-1B T-31C and TNF-A T-1031C by a duplex PCR-CTPP.   
Results: The eradication rate was 70.0% for RM, 93.9% for IM, and 85.7% for PM. The difference in the rate 
between RM and IM+PM was statistically significant (p=0.025). The eradication rate was highest for those with 
IL-1B -31CC; the p value was marginal among the whole subjects (χ2=3.78, p=0.05) and not significant among 
the RM group (χ2=1.60, p=0.21). The genotypes of TNF-A T-1031C had no associations with the eradication rate. 
But among the RM group, the odd ratio (OR) of the TNF-A CT for the eradication rate relative to TT was 
marginally reduced (OR=0.05, 95% confidence interval, 0.002-1.19). 
Conclusions: The present study confirmed the low eradication rate for RM. The reproduced finding provides 
evidence that the CYP2C19 genotype is useful to predict the success of the treatment. For the RM group, 
alternative regimens expected to be with a higher eradication rate will be recommended, especially to those with 
the TNF-A -1031C allele. 
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1.  Introduction 
Helicobacter pylori ( H. pylori) infection is an 
established cause of digestive diseases including ulcer, 
atrophic gastritis, stomach cancer, and 
mucosa-associated lymphoid tissue lymphoma [1-3]. 
Recent studies demonstrated that H. pylori eradication 
caused increase in platelets of patients with idiopathic 
thrombocytopenic purpura (ITP) [4,5]. Another study 
reported that the eradication may be useful to 
treatment of chronic urticaria, an autoimmune disease 
[6]. Arteriosclerosis is also presumed to be H. pylori 
–associated disease, though there is still controversy 
[7]. A study reported that infertility was associated 
with the seropositivity among men and women. In 
addition, they showed biological evidence that 
follicular fluid from infected women contained anti-H. 
pylori antibody, which reacted with spermatozoa [8].   
In Japan, health insurance covers H. pylori tests 
and eradication treatment for digestive ulcers, but not 
for the other diseases. Since are convinced the effect of 
the eradication on ITP treatment and the possibility of 
stomach cancer prevention at least among those who 
are successfully treated for early stomach cancer [9], 
there are increasing demands for H. pylori eradication 
treatment in Japan. In an international workshop held 
in Sweden, “the majority of the scientific task force 
favored a search-and-treat strategy in first-degree 
relatives of gastric cancer patients and an 
overwhelming majority felt that a more general 
screen-and-treat strategy should be focused in the first 
instance on a population with a high incidence of H. 
pylori-associated diseases” [10], which may include 
Japan, a high stomach cancer incidence country. The 
eradication was reported to be effective to reduce the 
medical care costs in the United Kingdom [11], and in 
Japan [12]. These expert recommendations/opinions 
may partly justify the H. pylori eradication for the 
more generalized populations in Japan. 
The treatments against H. pylori infection 
approved in Japanese health insurance are 7-day triple Int. J. Med. Sci. 2006, 3  136
therapies of lansoprazole (60mg) + amoxicillin 
(1,500mg) + clarithromycin (400mg) and omeprazole 
(40mg) + amoxicillin (1,500mg) + clarithromycin 
(800mg). The reported eradication rate for the former 
treatment was 87.5% in 96 patients with gastric ulcer 
and 91.1% in 90 patients with duodenal ulcer [13]. The 
rate for the latter treatment was reported to be 78.8% 
(n=113) by Kuwayama et al at the 7th annual scientific 
meeting of the Japanese Society of Helicobacter 
Research 2001. Since lansoprazole and omeprazole are 
metabolized by CYP2C19 in the liver, the functional 
genotypes of CYP2C19 could influence the eradication 
rate, as well as clarithromycin resistance of H. pylori. 
Concerning the lansoprazole-based triple therapy, 
there are two studies reporting the significant 
difference in the rate among those with different 
CYP2C19 genotypes [14] or with the different 
genotype combinations of CYP2C19 and IL-1B  [15], 
while other studies showed no significant association 
[16,17]. It was reported that those with the -511TT 
genotype of IL-1B encoding interleukin 1β, a potent 
gastric acid inhibiting proinflammatory cytokine, had 
a higher eradication rate relative to those with the 
-511CC genotype [18].   
This study aimed to examine the associations of 
the eradication rate with the functional 
polymorphisms of CYP2C19 G681A (*2) and G636A 
(*3), IL-1B T-31C tightly linked with C-511T [19], and 
TNF-A T-1031C. Since TNF-α encoded by TNF-A, is 
also a proinflammatory cytokine inhibiting gastric 
acid secretion 
[20], we 
hypothesized 
that the 
functional 
polymorphis
m of TNF-A 
may influence 
the 
eradication 
rate. The 
TNF-A  gene 
encoding 
TNF- α  is 
known to 
have five 
polymorphis
m in the 
promoter region; G-238A, G-308A, C-857T, C-863A, 
and T-1031C. Among Japanese, the -238A and -308A 
alleles are rare and C-863A is tightly linked with 
T-1031C. With respect to H. pylori seroposotivity, we 
have reported that the decreased OR of TNF-A 
-1031CC for H. pylori seropositivity relative to TT was 
significant, but the association with C-857T was not 
significant [21].   
This study was approved by the Ethics 
Committee of Nagoya University Graduate School of 
Medicine (approval number 155) on June 16, 2004. 
2.  Subjects and methods 
Study subjects 
Subjects were sampled from those visited Daiko 
Medical Center, Nagoya University, Nagoya, Japan to 
seek H. pylori tests and eradication between July 2004 
and October 2005. The visitors aged 20 to 69 years 
were asked to participate in the polymorphism study. 
Those who agreed with a written informed consent 
form to provide a 7ml of blood sample and to answer 
a questionnaire form on lifestyle including smoking 
habit, were enrolled in the present study. Any 
genotypes were not disclosed to the participants. The 
study protocol was approved by the ethics committee 
of the Nagoya University Graduate School of 
Medicine. 
Treatment for H. pylori infection 
Lansoprazole (30mg), amoxicillin (750mg), and 
clarithromycin (200mg) twice a day for 7 days (LAC 
regimen) were prescribed for those found to be 
infected with H. pylori by a 13C-urea breath test or 
serum anti-H. pylori antibody. More than one month 
after the medication, a 13C-urea breath test was 
conducted to examine the success/failure of the 
eradication treatment. 
Figure 1. The agarose gel electrophoresis for polymorphism 
at G681A and G636A of CYP2C19 by PCR with 
confronting. 
 
Genotyping 
DNA was extracted from the buffy coat by a 
BioRobot® EZ1 (QIAGEN Group, Tokyo) for 
genotyping  CYP2C19 G681A (*2) and G636A (*3), 
IL-1B T-31C, and TNF-A T-1031C. Genotypes were 
determined separately for the CYP2C19 
polymorphisms by polymerase chain reaction with 
confronting two-pair primers (PCR-CTPP) [22]. The 
primers for CYP2C19 G681A and G636A were *2F1: 5’ 
AGA GCT TGG CAT ATT GTA TCT, *2R1: 5’ TAA 
GTA ATT TGT TAT GGG TTC CC, *2F2: 5’ CCA CTA 
TCA TTG ATT ATT TCC CA, *2R2: 5’ TCG ATT CTT 
GGT GTT CTT TTA C, and *3F1: 5’ AAC CAG CTA Int. J. Med. Sci. 2006, 3  137
GGC TGT AAT TGT, *3R1: 5’ CTT GGC CTT ACC 
TGG ATC, *3F2: 5’ ATT GTA AGC ACC CCC TGA, 
*3R2: 5’ CAC TGA TCA GGG AGC TAA TG, 
respectively. The underlined are the bases of the single 
nucleotide polymorphism. Genomic DNA (30ng to 
100ng) was used per 25μl of reaction with 0.18mM 
dNTPs, 12.5 pmol of each primer, 0.5 units of 
"AmpliTaq Gold", and 2.5μl GeneAmp 10×PCR 
Buffer including 15mM MgCl2 (Perkin-Elmer Corp., 
Foster City, CA). Amplification conditions were 10 
minutes of initial denaturation at 95°C, followed by 30 
cycles of 1 minute at 95°C, 1 minute at 59°C for G681A 
and 58°C for G636A, and 1 minute at 72°C, then a 5 
minutes final extension at 72°C. The amplified DNA 
was visualized on a 2% agarose gel with ethidium 
bromide staining. A representative gel is shown in Fig. 
1. The alleles were distinguished as follows: a 131-bp 
band for the 681G allele and a 105-bp band for 681A 
allele, with a 191-bp their common band, and a 377-bp 
band for 636G allele and a 255-bp band for 636A allele, 
with a 597-bp their common band. IL-1B T-31C and 
TNF-A T-1031C were genotyped with a duplex 
PCR-CTPP described previously [23]. 
Statistical analysis 
Statistical analysis was performed using STATA 
Ver. 8 (College Station, TX) statistical software. The 
Hardy-Weinberg equilibrium, which indicates an 
absence of discrepancy between genotype and allele 
frequencies, was checked for the study subjects using a 
χ2 test. The odds ratios (ORs) and 95% confidence 
intervals (95% CIs)  were adjusted for sex 
(dichotomous) and age (a continuous variable) using 
an unconditional logistic regression model. 
3.  Results 
Table 1 describes the backgrounds of the whole 
visitors and participants.   
From July 2004 to October 2005, 210 persons 
visited the center. Among them, 142 were found to be 
infected, 165 participated in the polymorphism study 
and LAC were prescribed for 93 participants with H. 
pylori infection (in fact, 97 were prescribed eradication 
drug but 4 subjected who failed the eradication by 
LAC at other clinics were excluded because we dosed 
them metronidazole instead of clarithromycin). The 
distribution of the IL-1B T-31C, CYP2C19 G681A and 
G636A genes were in Hardy-Weinberg equilibrium 
(χ2=0.83 and p=0.36, χ2=0.72 and p=0.40, χ2=0.54 
and p=0.54, respectively), but the distribution of the 
TNF-A T-1031C gene was not (χ2=4.05, p=0.04). The 
difference of the distributions between the expected 
and observed from the TNF-A T-1031C gene was not 
substantial; 128.3 for 131, 34.4 for 29, and 2.3 for 5. The 
participant subjects were classified into three groups 
according to CYP2C19 genotype; rapid metabolizers 
(RM) with *1*1 genotype, intermediate metabolizers 
(IM) with *1*2  or  *1*3 genotype, and poor 
metabolizers (PM) with *2*2, *2*3, or  *3*3 genotype; 
*1*1, with the 681GG and 636GG; *1*2, with the 681GA 
and 636GG; *1*3 with the 681GG and 636GA; *2*2, 
with the 681AA and 636GG; *2*3, with the 681GA and 
636GA; *3*3, with the 681GG and 636AA.  
Table 1 Characteristics of the visitors and the participants 
in the polymorphism study 
Characteristics   Visitors  (n=210) 
      n   ( % )  
Participants (n=165) 
        n   ( % )  
Age    < 30 years  23 (11.0)  15 (9.1) 
 31-49  years  52 (24.8)  42 (25.5) 
 50-69  years  126 (60.0)  106 (64.2) 
  70 < years  9 (4.3)  2 (1.2) 
Sex  Males      91 (43.3)  74 (55.2) 
 Females  119 (56.7)  91 (44.9) 
Smokinga  Never  160 (76.6)  127 (77.0) 
 Former  25 (12.0)  19 (11.5) 
 Current  24 (11.5)  19 (11.5) 
H. pylorib Uninfected  65 (31.6)  55 (33.3) 
 Infecteted  142 (68.6)  110 (66.8) 
CYP2C19 RM  -  51  (30.9) 
 IM -  81  (49.1) 
 PM -  33  (20.0) 
IL-1B C-31Tc  TT -  48  (29.3) 
  CT -  76  (46.3) 
  CC -  40  (24.4) 
TNF-A C-1031T  TT     - 131  (79.4) 
  CT     - 29  (17.6) 
  CC      -  5  (3.0) 
a The information on the status of smoking was not available for one 
subject. 
b Three subjects among visitors did not take the examination on H. 
pylori infection. 
c One subject was not genotyped 
Table 2 The rate and odds ratios (ORs) of the eradication 
among the participants in the polymorphism study who 
were prescribed LAC and examined for the success/failure 
of the eradication. 
Factors   Treateda 
n 
Eradicated 
n (%) 
ORb  95%  CI 
Total   67  57  (85.1)   
Agec  < 30 years  1 0  (0.0)   
 31-49  years  14 10  (71.4)   
 50-69  years  52 47  (90.4)   
  70 < years  0 -   
Sex Females  33  29 (87.9)  1 (Reference) 
  Males  34  28 (82.4)  0.69 (0.17-2.82) 
CYP2C19  RM  20  14 (70.0)  1 (Reference) 
  IM  33  31 (93.9)  6.69 (1.12-39.9) 
  PM  14  12 (85.7)  4.35 (0.55-34.3) 
 IM+PM  47  43 (91.5)  5.72 (1.24-26.3) 
IL-1B  -31TT  17  13 (76.5)  1 (Reference) 
  -31CT  36  30 (83.3)  1.36 (0.31-5.96) 
  -31CC 14  14  (100)  ∞e 
IL-1Bd  -31TT  5  3 (60.0)  1 (Reference) 
  -31CT  12  8 (66.7)  0.45 (0.03-7.99) 
  -31CC 3 3  (100)  ∞f 
TNF-A  -1031TT  51  45 (85.1)  1 (Reference) 
  -1031CT  14  10 (71.4)  0.33 (0.07-1.51) 
  -1031CC  2 2  (100)  ∞g 
TNF-Ad  -1031TT  16  13 (81.3)  1 (Reference) 
  -1031CT  4  1 (25.0)  0.05 (0.002-1.19) 
  -1031CC  0 -  - 
Smoking  Never  49  43 (87.8)  1 (Reference) 
 Former  12  9 (75.0)  0.49 (0.08-3.00) 
 Current  6  5 (83.3)  0.82 (0.07-10.0) 
Smokingd  Never  16  12 (75.0)  1 (Reference) 
 Former  4  2 (50.0)  2.16 (0.12-40.5) 
 Current  0 -  - 
a participants in the polymorphism study who were prescribed LAC and 
examined for the success/failure of the eradication. 
b adjusted for sex and Int. J. Med. Sci. 2006, 3  138
age. 
c p=0.012 for 2 by 3 table using a  χ
2 test. 
 d Among the participants 
with the rapid metabolism. 
e,f,g Compared with reference by a  χ
2 test, the p 
values were 0.05, 0.21 and 0.61, respectively 
 
Table 2 shows the eradication rate for 67 
participants in the polymorphism study who were 
prescribed LAC and examined for the success/failure 
of the eradication. The combination of CYP2C19 IM 
and PM had a significantly high rate relative to RM. 
The eradication rate was highest for those with IL-1B 
-31CC but the p value was marginal (χ2=3.78, p=0.05). 
There were no differences in the eradication rate 
among those with different genotypes of TNF-A 
T-1031C. Among the rapid metabolizers, however, the 
decreased OR of TNF-A CT relative to TT was 
marginal (OR=0.05, 95% CI, 0.002-1.19). The OR for 
current and former smokers at the first visit was 0.82 
(95% CI, 0.07-10.0) and 0.49 (95% CI, 0.08-3.00), 
respectively. During the medication, two out of six 
current smokers quit smoking, three continued 
smoking, and one did not answer about smoking 
habit. 
4.  Discussion 
In the present study, CYP2C19 IM+PM showed a 
significantly high eradication rate relative to RM. 
Among the 10 failed, 6 were RM. The IL-1B T-31C 
polymorphism was associated with the eradication 
rate. Smoking during non-medication period did not 
affect the eradication rate. This was the first report on 
the possible association between the TNF-A 
polymorphism and the eradication rate among those 
with RM. 
The percentage of RM among those infected with 
H. pylori (31.2%) was similar to that of Japanese 
populations; by Furuta et al (32.6% of 141 subjects) [14], 
by Take et al (32.5% of 249 subjects) [15], by Kawabata 
et al (41.3% of 80 subjects) [16], and by Sugimoto et al 
(38.1% of 315 controls infected with H. pylori) [24]. 
Those percentages are much lower than those in 
Europe (81.1% of 143 subjects in Italy [25] and 73.3% 
of 60 subjects in Germany [26]). The allele frequencies 
for IL-1B -31T (0.536) and TNF-A -1031T (0.871) in this 
study were also similar to those among Japanese 
(0.558 of 1,062 chromosomes [27], and 0.835 of 2,742 
chromosomes [21], respectively), and lower and 
higher than that in Italy (0.669 and 0.768 of 1,288 
chromosomes, respectively) [28].   
To date, four studies examined the association of 
the eradication rate with the CYP2C19 genotypes. Two 
studies demonstrated non-significant results contrary 
to ours; in a randomized controlled study of 
lansoprazole versus rabeprazole for 187 patients with 
digestive ulcer by Kawabata et al [16], the eradication 
rate was 73% for 33 RM, 74% for 35 IM, and 83% for 12 
PM in the LAC group, and in the study by Miki et al 
[17], 83% for 12 RM, 85% for 26 IM, and 78% for 9 PM. 
Although the corresponding association is 
controversial, our present study  confirmed that the 
RM group relatively resistant to LAC should be 
treated with a more effective alternative regimen. 
Accordingly, the genotyping of CYP2C19 before 
eradication treatment could be useful to avoid the 
failure of treatment.   
The present study indicated that the 
polymorphism of IL-1B T-31C tightly linked with 
C-511T is one of the determinants on the result of H. 
pylori eradication. Among the RM group, IL-1B -31CC 
tended to show the highest eradication rate but the p 
value was not significant (χ2=1.60, p=0.21). Although 
the association with combinations of CYP2C19 and 
IL-1B C-511T was reported [15], our data did not reach 
significance, probably due to the small number of 
subjects analyzed.   
TNF-A  T-1031C  did not provide useful 
information to predict the result of the eradication 
treatment. But among the RM group, TNF-A T-1031C 
was useful as the indication of the success/failure of 
the eradication. TNF-A C-863A polymorphism linked 
tightly to T-1031C affects TNF-α expression; -863 A 
was associated with a lower serum TNF-α level.29 
Previously we have reported that TNF-A -1031TT was 
associated with persistent H. pylori infection and 
hypothesized that TNF-A -1031TT produces the high 
level of TNF-α, resulting in low gastric acid [21]. This 
study also indicated that those with the RM and 
TNF-A -1031CT genotype could not suppress gastric 
acid enough to eradicate H. pylori. Because this result 
was based on the small numbers, studies of a larger 
size are needed to confirm our finding.   
The problem of clarithromycin-resistant H. pylori 
is substantial in the eradication, but we could not 
determine the drug resistance because endoscopy was 
not conducted in our clinic. This is one of the 
limitations of this study. It was reported that the 
eradication rate was quite low among the RM group 
infected with clarithromycin-resistant H. pylori [14]. 
Take  et al reported that in a mulitivariate analysis, 
susceptibility to clarithromycin and CYP2C19 were 
significant factors, with IL-1B C-511T and smoking not 
significant, but the association of CYP2C19 genotype 
was marked only among those with IL-1B -511CC [15]. 
The relation between the TNF-A genotype and the 
eradication rate according to the status of H. pylori 
drug resistance remains to be elucidated.   
It has been well documented that smokers had a 
lower success probability of the eradication [30-32]. On 
the other hand, smokers who quit smoking during the 
medication reportedly had a higher eradication rate 
[32]. We strongly recommended to quit smoking 
during the medication, so two quit smoking at least 
during the medication and succeeded in H. pylori 
eradication. Since the smokers during the medication 
were four at most, eradication rate for smokers could 
not be estimated with an enough statistical power. 
In conclusion, the present study confirmed the 
low eradication rate among the RM who were treated 
with LAC. The reproduced finding provides evidence 
that the CYP2C19 and IL-1B genotype are useful to 
predict the success of the treatment. For the RM group, 
alternative regimens expected to be with a higher 
eradication rate will be recommended especially to 
those with the TNF-A -1031C allele. Further biological Int. J. Med. Sci. 2006, 3  139
investigation will be required to elucidate the 
association of these polymorphisms and the 
eradication rate. Based on the finding, we began in 
November 2005 to inform the participants of the 
CYP2C19 genotype to recommend another triple 
therapy (rabeprazole, metronidazole, and amoxicillin) 
for those with RM [16,33].   
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